lorazepam has been researched along with granisetron in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fell, GL; Leigh, TJ; Link, CG | 2 |
| Collis, C; Cunningham, J; Cunningham, S; Gandhi, L; Hamon, MD; Prentice, HG | 1 |
| Kaufman, MB | 1 |
| Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V | 1 |
| Cartwright, J; Frangoul, H; Ho, RH; Jones, E; Koyama, T; Kuttesch, J; Shankar, S; Whitlock, JA | 1 |
| Goldman, RD; Hasegawa, D; Kishimoto, K; Kosaka, Y; Ono, A | 1 |
1 review(s) available for lorazepam and granisetron
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for lorazepam and granisetron
| Article | Year |
|---|---|
Effects of granisetron and lorazepam, alone and in combination, on psychometric performance.
Topics: Adult; Drug Interactions; Flicker Fusion; Granisetron; Humans; Indazoles; Lorazepam; Male; Mental Processes; Middle Aged; Psychometrics; Psychomotor Performance; Reaction Time; Serotonin Antagonists; Single-Blind Method; Time Perception | 1991 |
Effects of granisetron and lorazepam, alone and in combination, on the EEG of human volunteers.
Topics: Adult; Double-Blind Method; Drug Interactions; Electroencephalography; Granisetron; Humans; Indazoles; Lorazepam; Male; Middle Aged; Random Allocation; Serotonin Antagonists | 1991 |
Granisetron in the prevention of irradiation-induced emesis.
Topics: Adult; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Granisetron; Humans; Lorazepam; Male; Metoclopramide; Vomiting; Whole-Body Irradiation | 1995 |
9 other study(ies) available for lorazepam and granisetron
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Adverse effects associated with dexamethasone, lorazepam, and granisetron.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dexamethasone; Female; Flushing; Granisetron; Head and Neck Neoplasms; Humans; Hyperemia; Infusions, Intravenous; Lorazepam | 1994 |
The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Haloperidol; Hematopoietic Stem Cell Transplantation; Humans; Lorazepam; Middle Aged; Nausea; Palliative Care; Treatment Outcome; Vomiting | 1998 |
Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confusion; Dexamethasone; Diphenhydramine; Drug Therapy, Combination; Female; Granisetron; Humans; Indoles; Infusion Pumps; Infusions, Intravenous; Length of Stay; Lorazepam; Male; Mood Disorders; Ondansetron; Patient Acceptance of Health Care; Quinolizines; Retrospective Studies; Self Administration; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Vomiting | 2007 |
Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia.
Topics: Adjuvants, Pharmaceutic; Adolescent; Adrenal Cortex Hormones; Anthracyclines; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Granisetron; Humans; Induction Chemotherapy; Infant; Lorazepam; Male; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quality of Life; Retrospective Studies; Risk Factors; Vomiting | 2019 |